Volvo Cars Plans 13 New Models by 2030 to Boost Sales 
Wall Street Surges as Meta Leads AI Rally, Oil Prices Fall 
CNN, MS NOW and Politico Sue Trump Over White House Media Ban 
Oil Prices Rise as Houthi Strikes on Riyadh Fuel Middle East Tensions 
Hyundai CEO Warns Chinese Automakers Could Disrupt US Market 
US-China Talks Target AI, Tariffs Ahead of Trump-Xi Summit 
Westinghouse Targets $50 Billion Valuation in U.S. IPO 
FAA Allows Boeing to Sell 35 More 777F Freighters Beyond 2028 
Yen in Focus as BOJ, Fed Rate Hikes Reshape Currency Markets 
Gold Prices Rise as Oil Slump Eases Fed Rate Hike Fears 
Asia Stocks Rise on AI Demand as Oil Eases 
UK Home Asking Prices Rise for First Time Since May 
Petrobras Joins Brazil’s New Diesel Subsidy Program 
Gold Prices Hold Steady Ahead of Trump-Xi Summit, Middle East Risks 
Apple Pay Set for India Launch With Axis Bank 
Vietnam, US Trade Deal Could Be Signed Soon, To Lam Says 
Add as a preferred source on Google
Samsung Biologics and Novartis International AG signed a contract manufacturing organization deal, and this was announced on Tuesday, June 7. The deal is worth $81 million.
According to The Korea Herald, the South Korean biotech company signed an intent letter for the CMO with the Swiss multinational pharmaceutical corporation. The agreement was announced via Samsung Biologics’ regulatory filing that also revealed that the companies signed the initial contract late last week.
Based on the report, the amount of the contract is equivalent to 6.41% of Samsung Biologics’ annual sales last year, which reached KRW1.57 trillion or around $1.25 billion. Then again, it was not mentioned which of Novartis’ biopharmaceutical products Samsung Biologics is producing under the CMO agreement.
The Korean biotech firm said that it would be releasing more deals in the future after both parties signed the main contract for their CMO partnership. The collab is said to be the first time Samsung Biologics is securing a deal from the Swiss pharmaceutical company.
“The letter of intent was the first contract between the two firms,” an official of Samsung Biologics stated. “We look forward to continuing to have cooperative relations through this deal in the future.”
The Korea Economic Daily reported that the latest deal increased Samsung Biologics’ total for CMO contracts to $400 million. The company has so far won orders from other multinational pharma firms such as GSK plc that is formerly known as GlaxoSmithKline plc, and Eli Lilly & Co. this year. In comparison, the firm was able to secure $1 billion worth of CMO contracts in 2021.
The South Korean CMO drugmaker obtained contracts from the top pharmaceutical firms in the world, including Bristol Myers Squibb, Roche, Johnson & Johnson, and Merck & Co. It was added that Samsung Biologics also has a contract with Gilead Sciences Inc. in the US.
Meanwhile, Samsung Biologics has been mostly manufacturing antibody treatments recently instead of cell-gene therapy (CGT). It has built up production facilities to make the drug substance for the messenger ribonucleic acid (mRNA)-based COVID-19 vaccines in its plant.
